USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Growth Opportunities in Human Microbiome Market, Forecast to 2023
Growth Opportunities in Human Microbiome Market, Forecast to 2023
Strategic Collaborations and Stakeholder Awareness Along with Clear Paths to Commercialization will Play a Key Role for Success in the Human Microbiome Market
06-Nov-2019
North America
Description
Interest in the microbiome as a science and industry has exploded over the past decade. Innovations are happening across 3 significant categories for human health benefits: microbiome-based therapeutics, over-the-counter (OTC) dietary supplements, and self-diagnostics/screening. The OTC market is the largest because of the lack of precise regulation, but the importance of therapeutic and diagnostic products is rapidly increasing with more research substantiating the potential of microbiome-based therapy. Diagnostic applications of the microbiome include the diagnosis of infections and monitoring of microbial components related to non-communicable, chronic diseases.
The effect of next-generation sequencing (NGS) and the disruptive response to genomics has resulted in the development of novel, biomarker-based diagnostics and screening tests that only detect microbiome interactions or presence in humans. These are either direct-to-consumer products for more robust evaluations.
Because microbiome-based therapies constitute an entirely new therapeutic category, there is much uncertainty about the best paths to commercialization The United States is expected to have a faster adoption due to higher interest and awareness generated in this field by the Food and Drug Administration (FDA). One of the critical challenges in microbiome research is deciding whether a particular change in the microbiota is accountable for a specific condition, or if it is a side effect. The complexity of the microbiome and the fact that each person has a distinct one makes it extremely difficult to determine cause-effect relationships.
The global demand for more effective medicines and healthier nutrition will continue to drive the development of microbiomic products. Advancements in genomic sequencing and computer algorithms are expected to create both medicines and therapeutics based on individual microbiomes for better outcomes and healthier lives that will prevent or minimize diseases.
Research Highlights
This study highlights the growth opportunities, visioning scenarios, innovative business models/use cases, competitive landscape, and key drivers and restraints, along with a revenue forecast for the human microbiome market.
Key Issues Addressed
- What is the market size and growth forecast for the human microbiome segments?
- Who are the key competitors in this market? How does the competitive landscape look like?
- What are the key growth opportunities for existing companies and new entrants in this market?
- What changes to the business model are required from companies to cater to changes in market conditions?
- How is the human microbiome market evolving? What are the key partnerships and collaborations in this industry?
- What are the strategic imperatives for human microbiome industry participants?
Table of Contents
Purpose of this Experiential Study
5-Step Process to Transformational Growth
Market Scope and Segmentation
Key Questions this Study will Answer
Market Snapshot
Market Engineering Measurements—Human Microbiome Market
Key Findings
Frost & Sullivan’s Big Market Prospects
Major Growth Opportunities
Microbiome Ecosystem—Industry Convergence Map
Strategic Imperatives for Growth
Market Definition
Key Types of Microbiome Therapeutics
Understanding Human Microbiome—Major Initiatives
Understanding Human Microbiome—Major Initiatives (continued)
Drivers and Restraints
Impact Mapping of Drivers and Restraints
Key Challenges in the Human Microbiome Market
Areas That Will Highly Impact Microbiome Adoption
Regulatory Scenario Assessment—OTC Segment
Regulatory Scenario Assessment—OTC Segment (continued)
Regulatory Scenario Assessment—Microbiome-based Drugs
Regulatory Scenario Assessment—Microbiome-based Drugs (continued)
Regulatory Scenario Assessment—Microbiome-based Drugs (continued)
Market Engineering Measurements—Human Microbiome Market
Forecast Assumptions
Revenue Forecast
Forecast Discussions
Revenue Forecast by Segment
Microbiome-based Drugs—Pipeline Analysis
Microbiome-based Drugs—Pipeline Analysis (continued)
Microbiome-based Drugs—Pipeline Analysis (continued)
Key Microbiome-based Drugs to Watch
Vendor Ecosystem
Key Companies to Watch—Enterome Bioscience
Key Companies to Watch—Chr. Hansen
Key Companies to Watch—Seres Therapeutics
Key Companies to Watch—Viome
Other Companies to Watch—Microbiome Therapeutics
Other Companies to Watch—Microbiome Diagnostics
Analysis of Big Pharma Spend on Human Microbiome Market
Analysis of Big Pharma Spend on Human Microbiome Market (continued)
Key Licensing Deals Analysis
Key Licensing Deals Analysis (continued)
Key Licensing Deals Analysis (continued)
Key Companies by Therapeutic Area of Focus and Stage of Microbiome Therapeutic Candidate
Human Microbiome Market—Macro to Micro Visioning
Key Future Trends in the Human Microbiome Market
Levers for Growth
Growth Opportunity 1—Microbiome-based Cancer Immunotherapies
Growth Opportunity 1—Microbiome-based Cancer Immunotherapies (continued)
Growth Opportunity 1—Microbiome-based Cancer Immunotherapies (continued)
Growth Opportunity 1—Microbiome-based Cancer Immunotherapies (continued)
Growth Opportunity 2—Personalized Medicine Through Microbiome Companion Diagnostics
Growth Opportunity 2—Personalized Medicine Through Microbiome Companion Diagnostics (continued)
Growth Opportunity 2—Personalized Medicine Through Microbiome Companion Diagnostics (continued)
Growth Opportunity 2—Personalized Medicine Through Microbiome Companion Diagnostics (continued)
Growth Opportunity 2—Personalized Medicine Through Microbiome Companion Diagnostics (continued)
Growth Opportunity 3—Wellness and Data Monetization Through DTCMT
Growth Opportunity 3—Wellness and Data Monetization Through DTCMT (continued)
Growth Opportunity 4—Microbiome (OTC and Therapeutic) Contract Manufacturing
Growth Opportunity 4—Microbiome (OTC and Therapeutic) Contract Manufacturing (continued)
Growth Opportunity Matrix
Focus Geographies for Human Microbiome Companies
Key Therapeutic Areas to Look Out for in Future
Strategic Imperatives for Human Microbiome Companies
3 Big Predictions
Legal Disclaimer
Research Till Date Has Identified Broadly 9 Therapy Areas Which Includes Multiple Chronic Diseases
List of Exhibits
List of Exhibits (continued)
Popular Topics
Research Highlights
This study highlights the growth opportunities, visioning scenarios, innovative business models/use cases, competitive landscape, and key drivers and restraints, along with a revenue forecast for the human microbiome market.
Key Issues Addressed
- What is the market size and growth forecast for the human microbiome segments?
- Who are the key competitors in this market? How does the competitive landscape look like?
- What are the key growth opportunities for existing companies and new entrants in this market?
- What changes to the business model are required from companies to cater to changes in market conditions?
- How is the human microbiome market evolving? What are the key partnerships and collaborations in this industry?
- What are the strategic imperatives for human microbiome industry participants?
| No Index | No |
|---|---|
| Podcast | No |
| Author | Saravanan Thangaraj |
| Industries | Healthcare |
| WIP Number | MECA-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,9562-B1,9571-B1,9573-B1,99C1-B1,99C6-B1,9568-B1,9611-B1,9627-B1 |